3 Global Stocks Estimated To Be Trading Below Fair Value
As global markets navigate the complexities of renewed U.S.-China trade tensions and concerns over a prolonged U.S. government shutdown, investors are carefully evaluating their portfolios amidst heightened geopolitical and economic uncertainty. With major indices showing mixed performance, the search for stocks trading below fair value becomes particularly compelling as investors look to identify opportunities that may offer resilience or potential growth in uncertain times.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Vimi Fasteners (BIT:VIM) |
€1.18 |
€2.32 |
49.2% |
|
Profoto Holding (OM:PRFO) |
SEK17.85 |
SEK35.19 |
49.3% |
|
Lingotes Especiales (BME:LGT) |
€5.70 |
€11.29 |
49.5% |
|
Kitron (OB:KIT) |
NOK58.65 |
NOK119.08 |
50.7% |
|
High Quality Food (BIT:HQF) |
€0.604 |
€1.21 |
49.9% |
|
Everest Medicines (SEHK:1952) |
HK$53.20 |
HK$105.04 |
49.4% |
|
Dizal (Jiangsu) Pharmaceutical (SHSE:688192) |
CN¥66.70 |
CN¥132.90 |
49.8% |
|
Bloomberry Resorts (PSE:BLOOM) |
₱3.85 |
₱7.66 |
49.8% |
|
Atea (OB:ATEA) |
NOK143.80 |
NOK282.84 |
49.2% |
|
Allegro.eu (WSE:ALE) |
PLN33.20 |
PLN66.10 |
49.8% |
Here’s a peek at a few of the choices from the screener.
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea and has a market cap of approximately ₩5.63 trillion.
Operations: The company’s revenue is primarily generated from its Pharmaceuticals segment, which accounts for approximately ₩449.81 billion.
Estimated Discount To Fair Value: 37.4%
PharmaResearch is trading 37.4% below its estimated fair value, with a forecasted revenue growth of 26.6% annually, surpassing the KR market’s growth rate. Earnings are expected to grow significantly at 31.8% per year, outpacing the market average. Recent strategic partnership with VIVACY for Rejuran distribution in Europe, valued at EUR 54.5 million over five years, enhances its international presence and could positively impact cash flows and valuation perceptions.
Overview: ST Pharm Co., Ltd. offers custom manufacturing services for active pharmaceutical ingredients and intermediates both in South Korea and internationally, with a market cap of ₩1.87 trillion.
Operations: The company’s revenue is primarily derived from raw material manufacturing, contributing ₩270.88 billion, and clinical trial contract research, which adds ₩31.30 billion.
